A total of 9928 cimetidine users were identified from prescriptions in four centres and followed for 10 years. The 'all-cause' mortality ratio fell from 1.9 in year 1 to 1.0 in years 8 to 10.
D G Colin-Jones, M J S Langman, D H Lawson, R F A Logan, K R Paterson, M P Vessey Abstract A total of 9928 cimetidine users were identified from prescriptions in four centres and followed for 10 years. The 'all-cause' mortality ratio fell from 1.9 in year 1 to 1.0 in years 8 to 10. Most ofthe early excess in mortality was attributable to cimetidine being given in the late stages of many diseases, often to counter adverse gastric effects of other drugs. Specific causes of mortality during years 5-10 of the study, were generally unremarkable. Significant increases in mortality ratios were apparent, however, for oesophageal cancer (years 5-7, 2-3; years 8-10, 1.9); lung cancer (years 5-7, 1 1; years 8-10, 1.7); diseases of the oesophagus, stomach, and duodenum (years 5-7, 3-3; years 8-10, 2.3); and chronic liver disease (years 5-7, 2.4; years 8-10, 3.3) . None of these increases in mortality seems to be attributable to an adverse effect of cimetidine use. Data are also presented for mortality from diseases of the nervous system. Eight deaths (of which one was miscoded) were certified as being from motor neurone disease, representing a mortality ratio of2.6 for years 2-10 ofthe study which is of borderline statistical significance. This study confirms that cimetidine is safe. Mortality from some diseases increased over the study period, but selection rather than any adverse effect of the drug is likely to be the explanation. (Gut 1992; 33: 1280 -1284 Our postmarketing surveillance study of the safety of cimetidine has already been described in earlier published reports on gastric cancer,'-2 mortality,`A and morbidity.5 The earlier reports should be consulted for details of subjects who died during the first four years of the study.'' We present here information about deaths that occurred during the subsequent six years and, in addition, complete mortality data to show the overall patterns.
Methods
The investigation was carried out in four centres - 4, 5, 6 , and 7 because recruitment was staggered, the OPCS introduced changes in the criteria for determining the UCD. In effect, these changes reduce the number of deaths from bronchopneumonia (conversion factor 2.2) and certain other non-specific illnesses and increases the number of deaths from some other diseases (for example endocrine diseases, mental disorders, and musculoskeletal disorders) in these and following years. Accordingly, the results for study years 5-10 are not strictly comparable with those described for previous years, although in practice the differences, apart from bronchopneumonia, are very small. In 1985, the OPCS Postmarketing surveillance ofthe safety ofcimetidine: 1Oyear mortality report (2) , motor neurone disease (MND) (8) , multiple sclerosis (MS) (4), hemiplegia (6), cerebral palsy (1) , pseudobulbar palsy (1), peripheral neuropathy of unknown cause (1). The deaths from Parkinson's disease were unremarkable. Three of the 4 MS patients had the disease before starting cimetidine and most of the other causes of death were associated with cerebrovascular disease. MND deaths were just significantly in excess (obs/exp 2.6), although small in number; one of these deaths was apparently misreported as being from MND (actually myelopathy due to severe cervical spondylosis) on the death certificate. One MND patient died aged 45 years. The diagnoses were all confirmed by neurologists and death occurred within 11-35 months. Two patients had probably stopped taking cimetidine two and four years before diagnosis ofthe disease, while five patients had taken many courses over several years before diagnosis. Two of these were virtually continuous courses but one patient was changed to ranitidine for three years before diagnosis. The 81 year old man with peripheral neuropathy recorded as the cause of death had also taken many courses of cimetidine but a large necrotic tumour had been removed from his bladder four months before the onset of symptoms.
The two deaths attributed to Alzheimer's disease occurred in men aged 82 and 73 years. There was no mention of the disease in the medical records and it was a doubtful diagnosis. There were three other mentions of Alzheimer's disease (not as the cause of death) on death certificates in years 2-10 but these numbers are not excessive and again two of these were doubtful diagnoses in elderly patients. Presenile dementia (ICD 290. 1) is a rubric sometimes used for patients with Alzheimer's disease but there were no deaths attributed to this cause. In years 2-10, we recorded three patients with presenile dementia mentioned on the death certificate; in at least two of these the disease was probably cerebrovascular in origin.
USE OF H2 RECEPTOR ANTAGONISTS
The simple questionnaire (n=690) sent to GPs showed that 20% of the subjects in our surviving cohort sample were using cimetidine in 1987, which was 9% less than in 1984. The use of ranitidine increased 8% from 1984 so that 15% of our sample were using this drug in 1987. The use of antisecretory drugs other than cimetidine and ranitidine was uncommon (around 1%). Of those using cimetidine, 41% received prescriptions in all quarters of the year and 27% in only one quarter. In the three centres for which information was available (Nottingham, Oxford, and Portsmouth), by years 8, 9, and 10, a constant 22% of those dying each year had used ranitidine in the past.
We looked at the diseases from which patients taking cimetidine in the last six months, last year, and last two years had died and compared them with patients who had not taken cimetidine in the three years before death. We could find no important differences. Neither was there any disease that was significantly associated with higher than usual prescription levels although, because of small numbers of deaths from some diseases, analysis was not always possible.
OTHER DIAGNOSES ON THE DEATH CERTIFICATE
We used the newly available data (for 1985) from the OPCS to look for any excesses among secondary diagnoses appearing on the death certificate in years 2-9. Even with eight years' combined data, we could not find anything of importance to add to our UCD analysis (UCD is, of course, a major component of 'all diagnoses' data). We have the impression that rheumatoid arthritis influenced the life span of some of our subjects, but over a period of years, the disease was only mentioned on death certificates 25 times, giving an obs/exp ratio of 2.2. The ratios for diabetes mellitus (obs/exp 0 8), senile dementia (obs/exp 0 9), hypertension (obs/exp 0 8) and emphysema (male obs/exp 0 2) were less than unity while those for peripheral vascular disease (male obs/exp 1.5), chronic bronchitis (male obs/exp 1.3), and renal failure (obs/exp 1.6) The excess of deaths from certain digestive disorders and from chronic liver disease and cirrhosis has followed the same pattern as in our last report and is attributable to the characteristics of the patients receiving cimetidine rather than to any adverse effect of the drug itself. It is notable that, even for these diseases, the observed to expected ratios have declined during the study from 6 3 in year 1 to 2 3 in years 8-10 for disorders of the oesophagus, stomach, etc. and from 17-3 in year 1 to 3-3 in years 8-10 for chronic liver disease. Likewise, the excess of deaths from pancreatitis in men seems to be related to alcohol misuse and to symptoms of the disease itself attracting prescriptions for cimetidine rather than to any more sinister factor.
Of the diseases of the nervous system, only the findings for MND are of interest, but one of the eight deaths was miscoded and the observed to expected ratio for years 2-10 of 2 6 is of only borderline statistical significance. Nonetheless in most cases, there was a clear history of long term use of cimetidine and this observation might warrant further study. The relevance, if any, of a recent study of xenobiotic metabolism in patients with MND is uncertain."
We also recorded two deaths from Alzheimer's disease in the nervous system group.
Unfortunately, death certificate data regarding Alzheimer's disease are very imprecise. Presenile dementia is sometimes used as a pseudonym, the disease tends to be reported as senile dementia as the patient ages, and the term Alzheimer's disease is sometimes used to avoid the stigma of dementia. Nevertheless, members of our cohort have presumably taken large amounts of aluminium containing antacids and there is no excess of deaths from Alzheimer's disease or any of the dementias or any excess of these diseases mentioned in other parts ofthe death certificate. 2 In conclusion, this study provides reassuring findings in a large cohort of cimetidine users after 10 years of follow up. We expect to continue to monitor mortality up to year 15.
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